Positive Efficacy Data in Murdoch Children’s Research Institute Urinary Tract Infection Animal Study
Highlights:
Murdoch Children’s Research Institutedata shows significant RECCE®327 (R327)
bactericidal activity againstEscherichia coliUrinary Tract Infections (UTI) in rat
model via intravenous infusion and new direct-to-bladder delivery
R327 is currently undergoing a Phase I/II UTI/Urosepsis Rapid Infusion Clinical
Trial to address needs at first patient presentation in GP and hospital settings
In 2019, >404.6m individualshad UTI’sglobally, ~80% resistant to two or more
antibiotics
Results of UTI study support potential for present Phase I/II Clinical Trial
Good results coming for patients - great to see
- Forums
- ASX - By Stock
- RCE
- Ann: Murdoch Children's R327 Efficacy UTI in-vivo
Ann: Murdoch Children's R327 Efficacy UTI in-vivo, page-2
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RCE (ASX) to my watchlist
|
|||||
Last
60.0¢ |
Change
0.030(5.26%) |
Mkt cap ! $122.3M |
Open | High | Low | Value | Volume |
56.5¢ | 62.0¢ | 56.5¢ | $158.1K | 263.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 77741 | 60.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
61.0¢ | 30000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 77741 | 0.600 |
1 | 1800 | 0.550 |
3 | 128518 | 0.540 |
2 | 41456 | 0.515 |
2 | 100000 | 0.510 |
Price($) | Vol. | No. |
---|---|---|
0.610 | 30000 | 1 |
0.620 | 19672 | 2 |
0.635 | 4250 | 1 |
0.650 | 15227 | 5 |
0.655 | 6970 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
RCE (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online